Assertio Therapeutics Inc (ASRT) Stock Price, Quote & News

Company Profile

Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut sy...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 224 419 7106

Fax: 510 744 8001

Website: www.assertiotx.com

Address:

100 South Saunders Road, Suite 300, Lake Forest, United States

Avedisian Apr. 3 at 3:13 PM

$ASRT The new journal paper released yesterday is promoting Rolvedon for 14 day regimen which its not prescribed for like Neulasta and biosimilars, its prescribed for next day and 21 day regimen only, this paper is promoting its safer for 14 day regimen also similar to Neulasta and biosimilar. They are trying to capture new mkts as well.

1 · Reply

Avedisian Apr. 3 at 4:59 AM

$ASRT Nice headline! https://tickeron.com/blogs/assertio-holdings-asrt-66-surge-in-30-days-on-earnings-beat-and-oncology-growth-12177/

0 · Reply

caddaly Apr. 2 at 4:13 PM

$ASRT so we are a dollar wide now.

0 · Reply

Avedisian Apr. 2 at 3:03 PM

$ASRT @D_S ASRT said they own 43% of medicare part B mkt in Q3 2025 earnings call, is there a way to find the TAM of this mkt to estimate Rolvedon sales ? These accounts could have been just won so need to give a year to see the revenue, it could have grown even more by Q4 2025.

1 · Reply

caddaly Apr. 2 at 2:18 PM

$ASRT there is some chart resistance around this level so it makes sense theres profit taking here. I do think eventually we bust through and then the chart becomes pretty favorable for a big run.

1 · Reply

AnchowersMyHero Apr. 2 at 2:03 PM

$ASRT way better volume at the start of the day, I would speculate this finally closes above $20. We shall see.

1 · Reply

Luckybreak Apr. 2 at 1:37 PM

$ASRT Hopefully stays positive today Dirt cheap stock/definitely possible

0 · Reply

Chuckuk Apr. 2 at 8:35 AM

$ASRT nasdaq pre this morning always gets me excited and mostly lets me down! Assertio Holdings, Inc. Common Stock (ASRT) Bid: $18.80 X 5 Ask: $29.21 X 100 Volume: 113,177 52 Week Range: 7.71 - 20.45

0 · Reply

caddaly Apr. 1 at 10:27 PM

$ASRT our baby is up over 4% today and not one post? Not even anything from Alve? Its a sorry state of afairs here.

2 · Reply

BioBiotech Mar. 31 at 10:28 PM

$UCAR Looks Like @latiio $ASRT 20 Dollar one day?

0 · Reply

Top 2 Health Care Stocks That May Implode In April

ALKS

Mar 16, 2026, 6:02 PM EDT - 19 days ago

Assertio Holdings, Inc. (ASRT) Q4 2025 Earnings Call Transcript

Mar 16, 2026, 4:05 PM EDT - 19 days ago

Assertio Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 3, 2026, 4:30 PM EST - 4 weeks ago

Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026

Jan 12, 2026, 4:15 PM EST - 2 months ago

Assertio Holdings, Inc. Regains Compliance With Nasdaq Listing Requirements

Jan 9, 2026, 1:45 PM EST - 3 months ago

Assertio Announces Publication of Rolvedon® Same-Day Dosing Clinical Trial

Dec 22, 2025, 4:30 PM EST - 3 months ago

Assertio Holdings, Inc. Announces 1-for-15 Reverse Stock Split

Nov 10, 2025, 6:21 PM EST - 5 months ago

Assertio Holdings, Inc. (ASRT) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 4:13 PM EST - 5 months ago

Assertio Reports Third Quarter 2025 Financial Results

Oct 28, 2025, 9:15 AM EDT - 5 months ago

Assertio Announces Leadership Transition

Sep 18, 2025, 5:06 PM EDT - 7 months ago

DEADLINE NEXT WEEK: Berger Montague Advises Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Investors to Contact the Firm Before September 24, 2025

Sep 15, 2025, 9:00 AM EDT - 7 months ago

Assertio Presents First-Ever Real-World Study Showing Patient Experience with SYMPAZAN® (clobazam) Oral Film, CIV

Sep 10, 2025, 7:30 AM EDT - 7 months ago

Assertio to Present New Data from Real-World Evidence Study of SYMPAZAN® at upcoming 150th Annual Meeting of the American Neurological Association

Sep 3, 2025, 8:15 AM EDT - 7 months ago

Assertio to Participate in the HC Wainwright and Lake Street Conferences in September 2025

Aug 11, 2025, 7:41 PM EDT - 8 months ago

Assertio Holdings, Inc. (ASRT) Q2 2025 Earnings Call Transcript

Aug 11, 2025, 4:05 PM EDT - 8 months ago

Assertio Reports Second Quarter 2025 Financial Results

Aug 6, 2025, 3:41 PM EDT - 8 months ago

Berger Montague PC Investigating Claims on Behalf of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Investors

Aug 5, 2025, 8:30 AM EDT - 8 months ago

Assertio Holdings, Inc. to Report Second Quarter 2025 Financial Results on August 11, 2025

May 19, 2025, 4:10 PM EDT - 11 months ago

Assertio to Participate in the Alliance Global Partners Healthcare Company Showcase on May 21, 2025

May 12, 2025, 8:17 PM EDT - 11 months ago

Assertio Holdings, Inc. (ASRT) Q1 2025 Earnings Call Transcript

May 12, 2025, 4:01 PM EDT - 11 months ago

Assertio Reports First Quarter 2025 Financial Results

May 5, 2025, 8:15 AM EDT - 11 months ago

Assertio Holdings, Inc. to Report First Quarter 2025 Financial Results on May 12, 2025

Mar 20, 2025, 9:10 AM EDT - 1 year ago

Assertio to Participate in the iAccess Alpha Virtual Best Ideas Conference on March 25-26, 2025

Mar 12, 2025, 6:53 PM EDT - 1 year ago

Assertio Holdings, Inc. (ASRT) Q4 2024 Earnings Call Transcript

Mar 12, 2025, 4:05 PM EDT - 1 year ago

Assertio Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 5, 2025, 4:05 PM EST - 1 year ago

Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 12, 2025

Jan 3, 2025, 4:30 PM EST - 1 year ago

Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Dec 17, 2024, 8:30 AM EST - 1 year ago

Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors

Dec 13, 2024, 8:00 AM EST - 1 year ago

Assertio Announces Results of Rolvedon® (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study

Nov 15, 2024, 9:00 AM EST - 1 year ago

Buxton Helmsley Calls for Senate Hearing on Well-Documented Evident Clinical Data Fraud at Assertio

Nov 11, 2024, 6:57 PM EST - 1 year ago

Assertio Holdings, Inc. (ASRT) Q3 2024 Earnings Call Transcript

Nov 11, 2024, 4:02 PM EST - 1 year ago

Assertio Reports Third Quarter 2024 Financial Results

Nov 11, 2024, 3:41 PM EST - 1 year ago

Buxton Helmsley Releases Evidence of Product-Related Fraud at Assertio

Nov 11, 2024, 7:30 AM EST - 1 year ago

Assertio Provides Response to Letter from Short-seller

Nov 8, 2024, 9:00 AM EST - 1 year ago

Buxton Helmsley Issues Letter to Assertio Stockholders Disclosing Inversion to Short Position Following Board Refusal to Address Product-Related Fraud

Oct 11, 2024, 8:00 AM EDT - 1 year ago

Assertio to Participate in the Maxim Group Healthcare Virtual Summit on October 15, 2024

Sep 11, 2024, 4:18 PM EDT - 1 year ago

Assertio Holdings: Management Change Could Improve Comeback Chances

Sep 3, 2024, 4:05 PM EDT - 1 year ago

Assertio to Participate in the HC Wainwright and Lake Street Conferences in New York City September 10-12, 2024

Aug 7, 2024, 9:45 PM EDT - 1 year ago

Assertio Holdings, Inc. (ASRT) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 4:01 PM EDT - 1 year ago

Assertio Reports Second Quarter 2024 Financial Results

Jul 24, 2024, 4:05 PM EDT - 1 year ago

Assertio Holdings, Inc. to Report Second Quarter 2024 Financial Results on August 7, 2024

Jul 24, 2024, 9:00 AM EDT - 1 year ago

Buxton Helmsley Issues Letter to the Board of Directors of Assertio Holdings, Inc.

Jun 27, 2024, 9:51 AM EDT - 1 year ago

Assertio: An Extremely Asymmetric Bet Skewed To The Upside

Jun 5, 2024, 8:30 AM EDT - 1 year ago

Assertio to Participate in the Sidoti Small Cap Conference on June 12, 2024

May 17, 2024, 9:15 AM EDT - 2 years ago

Assertio to Participate in Benchmark Healthcare Conference on May 21-22

Avedisian Apr. 3 at 3:13 PM

1 · Reply

Avedisian Apr. 3 at 4:59 AM

$ASRT Nice headline! https://tickeron.com/blogs/assertio-holdings-asrt-66-surge-in-30-days-on-earnings-beat-and-oncology-growth-12177/

0 · Reply

caddaly Apr. 2 at 4:13 PM

$ASRT so we are a dollar wide now.

0 · Reply

Avedisian Apr. 2 at 3:03 PM

1 · Reply

caddaly Apr. 2 at 2:18 PM

$ASRT there is some chart resistance around this level so it makes sense theres profit taking here. I do think eventually we bust through and then the chart becomes pretty favorable for a big run.

1 · Reply

AnchowersMyHero Apr. 2 at 2:03 PM

$ASRT way better volume at the start of the day, I would speculate this finally closes above $20. We shall see.

1 · Reply

Luckybreak Apr. 2 at 1:37 PM

$ASRT Hopefully stays positive today Dirt cheap stock/definitely possible

0 · Reply

Chuckuk Apr. 2 at 8:35 AM

$ASRT nasdaq pre this morning always gets me excited and mostly lets me down! Assertio Holdings, Inc. Common Stock (ASRT) Bid: $18.80 X 5 Ask: $29.21 X 100 Volume: 113,177 52 Week Range: 7.71 - 20.45

0 · Reply

caddaly Apr. 1 at 10:27 PM

$ASRT our baby is up over 4% today and not one post? Not even anything from Alve? Its a sorry state of afairs here.

2 · Reply

BioBiotech Mar. 31 at 10:28 PM

$UCAR Looks Like @latiio $ASRT 20 Dollar one day?

0 · Reply

TikStockTok Mar. 31 at 7:57 PM

$ASRT Looks quite nice!

0 · Reply

caddaly Mar. 31 at 4:22 PM

$ASRT sit and stay a while this time

0 · Reply

caddaly Mar. 31 at 4:21 PM

$ASRT well hello buyer. Nice to have you back today

1 · Reply

caddaly Mar. 31 at 4:20 PM

$ASRT maybe we get some m and a specualtion from this

0 · Reply

D_S Mar. 31 at 3:42 PM

$ASRT Here's a different link to the article ASRT restearchers put out. They compared Rolvedon to Neulesta and saw that the average patient is 7 years older and higher acuity https://jnccn.org/view/journals/jnccn/24/3.5/article-CLO26-092.xml

0 · Reply

Avedisian Mar. 31 at 3:29 PM

$ASRT New Journal article on Rolvedon, looks like Rolvedon is prescribed by oncologists for older population, perhaps considered safer without side effects, they seem to have a market here. https://jnccn.org/configurable/content/journals$002FJNCCN $002F24 $002F3.5$002FARTICLE-CLO26-092.xml?t%3Aac=journals%24002fjnccn%24002f24%24002f3.5%24002farticle-CLO26-092.xml&content=fullHtml-7602

0 · Reply

IBUYSELLHOLD Mar. 31 at 2:29 PM

$ASRT / there's still time to get in fbio!! Just closed 100+ million voucher sale!

0 · Reply

Avedisian Mar. 31 at 2:11 AM

$ASRT Investment analysts at HC Wainwright issued their Q1 2027 earnings estimates for Assertio in a report issued on Wednesday, March 18th. HC Wainwright analyst R. Selvaraju expects that the company will post earnings of $0.19 per share for the quarter. HC Wainwright currently has a "Buy" rating and a $35.00 price target on the stock. The consensus estimate for Assertio's current full-year earnings is $0.15 per share. HC Wainwright also issued estimates for Assertio's Q2 2027 earnings at $0.13 EPS, Q3 2027 earnings at $0.28 EPS, Q4 2027 earnings at $0.51 EPS and FY2027 earnings at $1.11 EPS.

4 · Reply

Chuckuk Mar. 30 at 7:58 PM

$ASRT Stocks go up and down and by the hour I have no idea why they take the direction they take.

1 · Reply

Luckybreak Mar. 30 at 6:35 PM

$ASRT Any which way you look at it this is dirt cheap

0 · Reply

caddaly Mar. 30 at 6:10 PM

$ASRT hurry up get out before its too late!

1 · Reply

11thestate Mar. 30 at 4:08 PM

With everything going on around $SPPI / $ASRT lately — this is the info you don’t want to miss: https://11th.com/cases/spectrum-investor-settlement

0 · Reply

Market Cap	123.81M
Revenue (ttm)	118.71M
Net Income (ttm)	-30.38M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	662.67
Profit Margin	-25.59%
Debt to Equity Ratio	0.42

Volume	126,500
Avg Vol	84,266
Day's Range	N/A - N/A
Shares Out	6.45M
Stochastic %K	84%
Beta	0.43
Analysts	Strong Sell
Price Target	$39.59